Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 15/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19906947 | 0.83 | P2RX7 (0.56) | P2RX7HPGD | |
| SCHEMBL19906592 | 0.81 | P2RX7 (0.55) | P2RX7BRD4 | |
| SCHEMBL19906464 | 0.81 | P2RX7 (0.55) | P2RX7HPGDBRD4 | |
| SCHEMBL19907176 | 0.81 | P2RX7 (0.56) | P2RX7 | |
| SCHEMBL19906588 | 0.80 | P2RX7 (0.64) | P2RX7 | |
| SCHEMBL9691998 | 0.80 | BRD4 (0.50) | P2RX7HPGDBRD4 | |
| SCHEMBL20215304 | 0.76 | P2RX7 (0.51) | P2RX7BRD4 | |
| SCHEMBL19906469 | 0.74 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL28495369 | 0.71 | HPGD (0.57) | P2RX7HPGDBRD4 | |
| SCHEMBL3996660 | 0.69 | HPGD (1.00) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292283-A1 | 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2021-09-23 | — | — | US | disclosed |
| US-11124486-B2 | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2021-09-21 | — | — | US | disclosed |
| EP-3287443-A1 | 6-MEMBERED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Shionogi & Co., Ltd (JP) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292283-A1 | 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, C1S | P2RX7 1458/4885HPGD 3782/4885BRD4 805/4885 |
| US-11124486-B2 | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, C1S | P2RX7 1324/4885HPGD 3653/4885BRD4 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.